BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Pedal Power: Divulging Well known Bike Brands for Each Cyclist - 24K televisions for Extreme Film Watching Experience
- 3What to expect from the planets in 2026 — key dates and sky events
- 4Exploring Being a parent: A Survey of \Bits of knowledge and Guidance for Guardians\ Nurturing Book
- 5Easy to understand Tech: Cell phones for Old in 2024
- 4 astronauts are en route home from ISS after medical issue forces early exit
- 6 Famous Urban communities for Shopping on the planet
- 5 Food varieties to Remember for Your Eating regimen for Ideal Wellbeing
- Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover
- Kiev declares energy emergency after Russian attacks amid winter cold
- Novo and Lilly cut prices of weight-loss drugs in China
- Magnetic fossils may reveal ancient creature's internal 'GPS system'
- No respite for German economy as experts slash forecast over Iran war
- Image of foreigners being arrested in S.Africa during Eid is AI-generated
